Comparing InMode (INMD) & The Competition

InMode (NASDAQ:INMD) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare InMode to similar businesses based on the strength of its profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Insider & Institutional Ownership

68.0% of InMode shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for InMode and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1	3	1	0	2.00
InMode Competitors	4291	10579	18364	831	2.46

InMode currently has a consensus target price of $16.33, indicating a potential upside of 22.44%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.72%. Given InMode’s higher probable upside, equities research analysts plainly believe InMode is more favorable than its competitors.

Earnings and Valuation

This table compares InMode and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InMode	$374.62 million	$93.83 million	10.85
InMode Competitors	$1.90 billion	$135.83 million	5.88

InMode’s competitors have higher revenue and earnings than InMode. InMode is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

InMode has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, InMode’s competitors have a beta of 2.57, indicating that their average share price is 157% more volatile than the S&P 500.

Profitability

This table compares InMode and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
InMode Competitors	-304.20%	-315.07%	-22.11%

Summary

InMode competitors beat InMode on 7 of the 13 factors compared.

InMode Company Profile

InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.